Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards
This article was originally published in PharmAsia News
Executive Summary
Samsung Biologics halts ongoing clinical trials across 16 countries for its Rituxan biosimilar as it seeks clarity on emerging regulatory guidelines by U.S. FDA.